- Home
- RLGT vs SGMT Comparison
RLGT vs SGMT Comparison
Compare RLGT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLGT
- SGMT
- Stock Information
- Founded
- RLGT 2001
- SGMT 2006
- Country
- RLGT United States
- SGMT United States
- Employees
- RLGT N/A
- SGMT N/A
- Industry
- RLGT Oil Refining/Marketing
- SGMT
- Sector
- RLGT Consumer Discretionary
- SGMT
- Exchange
- RLGT Nasdaq
- SGMT Nasdaq
- Market Cap
- RLGT 283.4M
- SGMT 238.7M
- IPO Year
- RLGT N/A
- SGMT 2023
- Fundamental
- Price
- RLGT $6.06
- SGMT $8.47
- Analyst Decision
- RLGT Strong Buy
- SGMT Strong Buy
- Analyst Count
- RLGT 1
- SGMT 8
- Target Price
- RLGT $8.00
- SGMT $26.88
- AVG Volume (30 Days)
- RLGT 166.7K
- SGMT 563.6K
- Earning Date
- RLGT 11-10-2025
- SGMT 11-13-2025
- Dividend Yield
- RLGT N/A
- SGMT N/A
- EPS Growth
- RLGT 72.35
- SGMT N/A
- EPS
- RLGT 0.31
- SGMT N/A
- Revenue
- RLGT $925,786,000.00
- SGMT N/A
- Revenue This Year
- RLGT $2.96
- SGMT N/A
- Revenue Next Year
- RLGT $2.98
- SGMT N/A
- P/E Ratio
- RLGT $19.32
- SGMT N/A
- Revenue Growth
- RLGT 16.42
- SGMT N/A
- 52 Week Low
- RLGT $5.44
- SGMT $1.73
- 52 Week High
- RLGT $7.94
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- RLGT 48.99
- SGMT 56.97
- Support Level
- RLGT $6.04
- SGMT $7.02
- Resistance Level
- RLGT $6.28
- SGMT $8.06
- Average True Range (ATR)
- RLGT 0.14
- SGMT 0.64
- MACD
- RLGT 0.01
- SGMT -0.00
- Stochastic Oscillator
- RLGT 45.78
- SGMT 60.86
About RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.